Mary Caffrey

Medicaid expansion has enhanced cancer care in Louisiana, boosting access to treatments like CAR T-cell therapy and improving breast cancer screening initiatives.

The FDA approved epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a promising fixed-duration treatment option for patients after their first relapse.

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

A white paper explores how biomarker testing enhances patient outcomes and what barriers prevent access in several common cancers.

Leaders from The US Oncology Network and McKesson discuss how technology can enhance precision medicine and improve patient access to cutting-edge cancer treatments.

Experts discuss strategies for equitable access to genomic testing and cutting-edge therapies for uninsured non-small cell lung cancer patients.

Explore the future of cancer treatment with tumor-agnostic therapies, as experts unveil promising trials and innovative drug developments at ESMO.

A study reveals promising results for combining enfortumab vedotin and pembrolizumab in treating recurrent head and neck cancer, showing a 39% response rate.

IO Biotech's immune-modulatory cancer vaccine combination shows promise in advanced melanoma, despite missing statistical significance for PFS.

New findings reveal that combining Pluvicto with standard therapies significantly improves outcomes for patients with prostate cancer, enhancing quality of life.

Experts at the European Society for Medical Oncology Congress meeting in Berlin, Germany, explore rising cancer rates in young adults, focusing on survivorship challenges and the role of lifestyle interventions in care.

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.

Experts at ESMO Congress highlighted the urgent need for open discussions on sexual health post cancer treatment, emphasizing its impact on quality of life.

Combination therapy with enfortumab vedotin and pembrolizumab significantly reduces progression and mortality risk of muscle invasive bladder cancer in first-line treatment.

Results presented at ESMO show zongertinib produced 79% PFS at 6 months and nearly half of patients remained on treatment at the data cutoff. Investigators reported strong efficacy and tolerability in first-line treatment of advanced HER2-mutant NSCLC.

ESMO Congress 2025 in Berlin showcases breakthroughs in precision medicine for bladder, breast, lung, and prostate cancers, enhancing patient quality of life.

Coverage from a Stakeholder Interchange hosted by The American Journal of Managed Care,® August 21, 2025. This is a moderated discussion of 3 case studies.

Coverage from a Stakeholder Interchange hosted by The American Journal of Managed Care,® August 21, 2025. A moderator led panelists through a discussion of issues surrounding administration of bispecifics in multiple myeloma.

Expanding clinical trial eligibility in slow-developing follicular lymphoma enhances patient access to innovative therapies and addresses healthcare disparities.

Blood Cancer United, formerly Leukemia & Lymphoma Society, aims to enhance awareness and support for blood cancer patients during Blood Cancer Awareness Month.

Explore cutting-edge discussions on patient-centered oncology, value-based care, AI innovations, and survivorship strategies Thursday and Friday at PCOC 2025 in Nashville.

Remote patient monitoring enhances cancer care by improving outcomes and reducing emergency visits, despite challenges in reimbursement and technology access.

Outpatient treatment with axi-cel shows promising response rates for relapsed large B-cell lymphoma, enhancing accessibility in community oncology settings.

Zanubrutinib shows superior progression-free and overall survival in relapsed mantle cell lymphoma compared with acalabrutinib, according to a new analysis.

Community oncology leaders navigate challenges in value-based care under the Enhancing Oncology Model, facing performance payment uncertainties and evolving drug markets.

The FDA's removal of REMS for CAR T-cell therapies enhances access for community oncology, paving the way for innovative treatments and improved patient outcomes.